Loading...

Donald Durden

TitleProfessor
InstitutionUniversity of California San Diego
DepartmentPediatrics
Address9500 Gilman Drive #0815
La Jolla CA 92093
Phone858-534-3355
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    A Phase I study of a dual PI3K/BRD4 inhibitor, SF1126 in the treatment of hepatocellular carcinoma | IDE: 74,551
    NIH R01FD005113Sep 30, 2016 - Aug 31, 2020
    Role: Principal Investigator
    Maximizing cancer synthetic lethality using dual PI-3K/PARP inhibitors
    NIH R41CA206859Sep 22, 2016 - Sep 19, 2017
    Role: Principal Investigator
    Maximal MYC control using dual PI-3K/BRD4 (kinase/epigenetic) inhibitors
    NIH R41CA192656Apr 8, 2015 - Mar 31, 2016
    Role: Principal Investigator
    Phase 2 Study of Poly-ICLC in the Treatment of Pediatric Low Grade Gliomas
    NIH R01FD004385Sep 5, 2014 - Jul 31, 2018
    Role: Principal Investigator
    Role of Syk and Rac2 in regulation of HIF1alpha and neovascularization.
    NIH R21HL091385Jul 1, 2009 - Jun 30, 2011
    Role: Principal Investigator
    Role of Rac2 in Development and Function of Blood Cells
    NIH P01HL069974Apr 22, 2002 - Mar 31, 2008
    Role: Co-Investigator
    Vascular targeted pan PI-3 kinase inhibitor prodrug, SF1126 for glioma therapy
    NIH R01CA094233Dec 1, 2001 - Mar 31, 2013
    Role: Principal Investigator
    Vascular targeted pan PI-3kinase inhibitor prodrug, SF1126 for glioma therapy.
    NIH R56CA094233Dec 1, 2001 - Jun 30, 2009
    Role: Principal Investigator
    Biology and Therapy of High Risk Neuroblastoma
    NIH/NCI P01CA081403Jul 6, 2000 - May 31, 2015
    Role: Co-Investigator
    PHASE II STUDY FOR TREATMENT OF PEDIATRIC BRAIN TUMORS
    NIH R01CA075637Sep 15, 1997 - Jul 31, 2000
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Cooke EJ, Zhou JY, Wyseure T, Joshi S, Bhat V, Durden D, Mosnier LO, Drygalski AV. Vascular Permeability and Remodelling Coincide with Inflammatory and Reparative Processes after Joint Bleeding in Factor VIII-Deficient Mice. Thromb Haemost. 2018 Jun; 118(6):1036-1047. PMID: 29847841.
      View in: PubMed
    2. Campbell GR, Bruckman RS, Herns SD, Joshi S, Durden D, Spector SA. Induction of autophagy by PI3K/MTOR and PI3K/MTOR/BRD4 inhibitors suppresses HIV-1 replication. J Biol Chem. 2018 Apr 20; 293(16):5808-5820. PMID: 29475942.
      View in: PubMed
    3. Joshi S, Singh AR, Wong SS, Zulcic M, Jiang M, Pardo A, Selman M, Hagood JS, Durden D. Rac2 is required for alternative macrophage activation and bleomycin induced pulmonary fibrosis; a macrophage autonomous phenotype. PLoS One. 2017; 12(8):e0182851. PMID: 28817691.
      View in: PubMed
    4. Nguyen HA, Durden D, Lavie A. The differential ability of asparagine and glutamine in promoting the closed/active enzyme conformation rationalizes the Wolinella succinogenes L-asparaginase substrate specificity. Sci Rep. 2017 Jan 31; 7:41643. PMID: 28139703.
      View in: PubMed
    5. Andrews FH, Singh AR, Joshi S, Smith CA, Morales GA, Garlich JR, Durden D, Kutateladze TG. Dual-activity PI3K-BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis. Proc Natl Acad Sci U S A. 2017 02 14; 114(7):E1072-E1080. PMID: 28137841.
      View in: PubMed
    6. Erdreich-Epstein A, Singh AR, Joshi S, Vega FM, Guo P, Xu J, Groshen S, Ye W, Millard M, Campan M, Morales G, Garlich JR, Laird PW, Seeger RC, Shimada H, Durden D. Association of high microvessel avß3 and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126. Oncotarget. 2017 Aug 08; 8(32):52193-52210. PMID: 28881723.
      View in: PubMed
    7. Singh AR, Joshi S, Burgoyne AM, Sicklick JK, Ikeda S, Kono Y, Garlich JR, Morales GA, Durden D. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma. Mol Cancer Ther. 2016 11; 15(11):2553-2562. PMID: 27496136.
      View in: PubMed
    8. Singh AR, Joshi S, Zulcic M, Alcaraz M, Garlich JR, Morales GA, Cho YJ, Bao L, Levy ML, Newbury R, Malicki D, Messer K, Crawford J, Durden D. PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma. PLoS One. 2016; 11(3):e0150836. PMID: 26938241; PMCID: PMC4777592.
    9. Ishii Y, Nhiayi MK, Tse E, Cheng J, Massimino M, Durden D, Vigneri P, Wang JY. Knockout Serum Replacement Promotes Cell Survival by Preventing BIM from Inducing Mitochondrial Cytochrome C Release. PLoS One. 2015; 10(10):e0140585. PMID: 26473951; PMCID: PMC4608728.
    10. Bhat V, Olmer M, Joshi S, Durden D, Cramer TJ, Barnes RF, Ball ST, Hughes TH, Silva M, Luck JV, Moore RE, Mosnier LO, von Drygalski A. Vascular remodeling underlies rebleeding in hemophilic arthropathy. Am J Hematol. 2015 Nov; 90(11):1027-35. PMID: 26257191; PMCID: PMC4618067 [Available on 11/01/16].
    11. Joshi S, Singh AR, Durden D. Pan-PI-3 kinase inhibitor SF1126 shows antitumor and antiangiogenic activity in renal cell carcinoma. Cancer Chemother Pharmacol. 2015 Mar; 75(3):595-608. PMID: 25578041.
      View in: PubMed
    12. Singh AR, Joshi S, George E, Durden D. Anti-tumor effect of a novel PI3-kinase inhibitor, SF1126, in (12)?V-Ha-Ras transgenic mouse glioma model. Cancer Cell Int. 2014; 14(1):105. PMID: 25425962; PMCID: PMC4243316.
    13. Joshi S, Singh AR, Zulcic M, Durden D. A macrophage-dominant PI3K isoform controls hypoxia-induced HIF1a and HIF2a stability and tumor growth, angiogenesis, and metastasis. Mol Cancer Res. 2014 Oct; 12(10):1520-31. PMID: 25103499.
      View in: PubMed
    14. Hartman LL, Crawford JR, Makale MT, Milburn M, Joshi S, Salazar AM, Hasenauer B, VandenBerg SR, MacDonald TJ, Durden D. Pediatric phase II trials of poly-ICLC in the management of newly diagnosed and recurrent brain tumors. J Pediatr Hematol Oncol. 2014 Aug; 36(6):451-7. PMID: 24309609; PMCID: PMC4356196.
    15. Joshi S, Singh AR, Durden D. MDM2 regulates hypoxic hypoxia-inducible factor 1a stability in an E3 ligase, proteasome, and PTEN-phosphatidylinositol 3-kinase-AKT-dependent manner. J Biol Chem. 2014 Aug 15; 289(33):22785-97. PMID: 24982421; PMCID: PMC4132784.
    16. Singh AR, Peirce SK, Joshi S, Durden D. PTEN and PI-3 kinase inhibitors control LPS signaling and the lymphoproliferative response in the CD19+ B cell compartment. Exp Cell Res. 2014 Sep 10; 327(1):78-90. PMID: 24881819.
      View in: PubMed
    17. Joshi S, Singh AR, Zulcic M, Durden D. A PKC-SHP1 signaling axis desensitizes Fc? receptor signaling by reducing the tyrosine phosphorylation of CBL and regulates Fc?R mediated phagocytosis. BMC Immunol. 2014 May 07; 15:18. PMID: 24886428; PMCID: PMC4017086.
    18. Joshi S, Singh AR, Zulcic M, Bao L, Messer K, Ideker T, Dutkowski J, Durden D. Rac2 controls tumor growth, metastasis and M1-M2 macrophage differentiation in vivo. PLoS One. 2014; 9(4):e95893. PMID: 24770346; PMCID: PMC4000195.
    19. Muh CR, Joshi S, Singh AR, Kesari S, Durden D, Makale MT. PTEN status mediates 2ME2 anti-tumor efficacy in preclinical glioblastoma models: role of HIF1a suppression. J Neurooncol. 2014 Jan; 116(1):89-97. PMID: 24162827; PMCID: PMC3896301.
    20. Morales GA, Garlich JR, Su J, Peng X, Newblom J, Weber K, Durden D. Synthesis and cancer stem cell-based activity of substituted 5-morpholino-7H-thieno[3,2-b]pyran-7-ones designed as next generation PI3K inhibitors. J Med Chem. 2013 Mar 14; 56(5):1922-39. PMID: 23410005.
      View in: PubMed
    21. De P, Dey N, Terakedis B, Bergsagel PL, Li ZH, Mahadevan D, Garlich JR, Trudel S, Makale MT, Durden D. An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo. Cancer Chemother Pharmacol. 2013 Apr; 71(4):867-81. PMID: 23355037; PMCID: PMC3832139.
    22. Peirce SK, Findley HW, Prince C, Dasgupta A, Cooper T, Durden D. The PI-3 kinase-Akt-MDM2-survivin signaling axis in high-risk neuroblastoma: a target for PI-3 kinase inhibitor intervention. Cancer Chemother Pharmacol. 2011 Aug; 68(2):325-35. PMID: 20972874; PMCID: PMC3143317.
    23. Castellino RC, Barwick BG, Schniederjan M, Buss MC, Becher O, Hambardzumyan D, Macdonald TJ, Brat DJ, Durden D. Heterozygosity for Pten promotes tumorigenesis in a mouse model of medulloblastoma. PLoS One. 2010 May 26; 5(5):e10849. PMID: 20520772; PMCID: PMC2877103.
    24. Crosswell HE, Dasgupta A, Alvarado CS, Watt T, Christensen JG, De P, Durden D, Findley HW. PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells. BMC Cancer. 2009 Nov 25; 9:411. PMID: 19939254; PMCID: PMC2790467.
    25. Ozbay T, Durden D, Liu T, O'Regan RM, Nahta R. In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells. Cancer Chemother Pharmacol. 2010 Mar; 65(4):697-706. PMID: 19636556; PMCID: PMC2808522.
    26. Gu L, Zhu N, Zhang H, Durden D, Feng Y, Zhou M. Regulation of XIAP translation and induction by MDM2 following irradiation. Cancer Cell. 2009 May 05; 15(5):363-75. PMID: 19411066; PMCID: PMC2696306.
    27. Rong Y, Belozerov VE, Tucker-Burden C, Chen G, Durden D, Olson JJ, Van Meir EG, Mackman N, Brat DJ. Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity. Cancer Res. 2009 Mar 15; 69(6):2540-9. PMID: 19276385; PMCID: PMC2759716.
    28. De P, Peng Q, Traktuev DO, Traktuevc DO, Li W, Yoder MC, March KL, Durden D. Expression of RAC2 in endothelial cells is required for the postnatal neovascular response. Exp Cell Res. 2009 Jan 15; 315(2):248-63. PMID: 19123268; PMCID: PMC2767303.
    29. Dey N, Crosswell HE, De P, Parsons R, Peng Q, Su JD, Durden D. The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration. Cancer Res. 2008 Mar 15; 68(6):1862-71. PMID: 18339867.
      View in: PubMed
    30. Garlich JR, De P, Dey N, Su JD, Peng X, Miller A, Murali R, Lu Y, Mills GB, Kundra V, Shu HK, Peng Q, Durden D. A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res. 2008 Jan 01; 68(1):206-15. PMID: 18172313.
      View in: PubMed
    31. Li Y, Yan J, De P, Chang HC, Yamauchi A, Christopherson KW, Paranavitana NC, Peng X, Kim C, Munugalavadla V, Munugulavadla V, Kapur R, Chen H, Shou W, Stone JC, Kaplan MH, Dinauer MC, Durden D, Quilliam LA. Rap1a null mice have altered myeloid cell functions suggesting distinct roles for the closely related Rap1a and 1b proteins. J Immunol. 2007 Dec 15; 179(12):8322-31. PMID: 18056377; PMCID: PMC2722108.
    32. Castellino RC, Durden D. Mechanisms of disease: the PI3K-Akt-PTEN signaling node--an intercept point for the control of angiogenesis in brain tumors. Nat Clin Pract Neurol. 2007 Dec; 3(12):682-93. PMID: 18046441.
      View in: PubMed
    33. Dey N, De PK, Wang M, Zhang H, Dobrota EA, Robertson KA, Durden D. CSK controls retinoic acid receptor (RAR) signaling: a RAR-c-SRC signaling axis is required for neuritogenic differentiation. Mol Cell Biol. 2007 Jun; 27(11):4179-97. PMID: 17325034; PMCID: PMC1900023.
    34. Reinert RB, Oberle LM, Wek SA, Bunpo P, Wang XP, Mileva I, Goodwin LO, Aldrich CJ, Durden D, McNurlan MA, Wek RC, Anthony TG. Role of glutamine depletion in directing tissue-specific nutrient stress responses to L-asparaginase. J Biol Chem. 2006 Oct 20; 281(42):31222-33. PMID: 16931516.
      View in: PubMed
    35. Rong Y, Hu F, Huang R, Mackman N, Horowitz JM, Jensen RL, Durden D, Van Meir EG, Brat DJ. Early growth response gene-1 regulates hypoxia-induced expression of tissue factor in glioblastoma multiforme through hypoxia-inducible factor-1-independent mechanisms. Cancer Res. 2006 Jul 15; 66(14):7067-74. PMID: 16849552; PMCID: PMC2610484.
    36. Rong Y, Durden D, Van Meir EG, Brat DJ. 'Pseudopalisading' necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J Neuropathol Exp Neurol. 2006 Jun; 65(6):529-39. PMID: 16783163.
      View in: PubMed
    37. Dey N, Howell BW, De PK, Durden D. CSK negatively regulates nerve growth factor induced neural differentiation and augments AKT kinase activity. Exp Cell Res. 2005 Jul 01; 307(1):1-14. PMID: 15890337.
      View in: PubMed
    38. Rong Y, Post DE, Pieper RO, Durden D, Van Meir EG, Brat DJ. PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res. 2005 Feb 15; 65(4):1406-13. PMID: 15735028.
      View in: PubMed
    39. Moon KD, Post CB, Durden D, Zhou Q, De P, Harrison ML, Geahlen RL. Molecular basis for a direct interaction between the Syk protein-tyrosine kinase and phosphoinositide 3-kinase. J Biol Chem. 2005 Jan 14; 280(2):1543-51. PMID: 15536084.
      View in: PubMed
    40. Pradip D, Peng X, Durden D. Rac2 specificity in macrophage integrin signaling: potential role for Syk kinase. J Biol Chem. 2003 Oct 24; 278(43):41661-9. PMID: 12917394.
      View in: PubMed
    41. Su JD, Mayo LD, Donner DB, Durden D. PTEN and phosphatidylinositol 3'-kinase inhibitors up-regulate p53 and block tumor-induced angiogenesis: evidence for an effect on the tumor and endothelial compartment. Cancer Res. 2003 Jul 01; 63(13):3585-92. PMID: 12839945.
      View in: PubMed
    42. Erdreich-Epstein A, Tran LB, Bowman NN, Wang H, Cabot MC, Durden D, Vlckova J, Reynolds CP, Stins MF, Groshen S, Millard M. Ceramide signaling in fenretinide-induced endothelial cell apoptosis. J Biol Chem. 2002 Dec 20; 277(51):49531-7. PMID: 12388538.
      View in: PubMed
    43. Kant AM, De P, Peng X, Yi T, Rawlings DJ, Kim JS, Durden D. SHP-1 regulates Fcgamma receptor-mediated phagocytosis and the activation of RAC. Blood. 2002 Sep 01; 100(5):1852-9. PMID: 12176909.
      View in: PubMed
    44. Kim JS, Peng X, De PK, Geahlen RL, Durden D. PTEN controls immunoreceptor (immunoreceptor tyrosine-based activation motif) signaling and the activation of Rac. Blood. 2002 Jan 15; 99(2):694-7. PMID: 11781256.
      View in: PubMed
    45. Mayo LD, Dixon JE, Durden D, Tonks NK, Donner DB. PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J Biol Chem. 2002 Feb 15; 277(7):5484-9. PMID: 11729185.
      View in: PubMed